• Hirohisa Yajima, Hideaki Kanaya, Masahiro Ogino, Keisuke Ueki, and Phyo Kim.
• Department of Neurosurgery, Dokkyo Medical University Hospital, Tochigi, Japan.
• Clin Neurol Neurosurg. 2020 Oct 1; 197: 106097.

BackgroundMiddle meningeal artery (MMA) embolization can be a treatment option for selected cases of chronic subdural hematoma (CSDH) patients. However, appropriate timing of this procedure or the conditions to be considered are still not standardized.MethodsBetween 2008 and 2018, 18 symptomatic CSDH patients underwent MMA embolization at our institution. The timing of embolization and the risk factors for recurrence of CSDH, the recurrence rate after an embolization, and the complication were thoroughly reviewed.ResultsOf the 18 cases, 16 patients were male. The median age at MMA embolization was 78.5 years (range, 66-98 years). The median follow-up period were eight months (range, 2-53 months). Possible risk factors for CSDH recurrence harbored by those patients were age > 74 yrs (10), brain atrophy (4), separated hematoma (3), coagulopathy (3), anticoagulant administration (3), and thrombocytopenia (1). No recurrence or complication was observed in any of the patients after the embolization.ConclusionsMMA embolization is effective and safe in preventing recurrence of CSDH with high risk of recurrence, and could be a standard treatment for such cases.Copyright © 2020 Elsevier B.V. All rights reserved.

25 keywords...

hide…